Anaplastic lymphoma kinase-positive large B-cell lymphoma: A distinct clinicopathological entity

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 6, 2009, Pages 508-518

  Li, Shiyong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALK; Anaplastic lymphoma kinase; CLTC ALK; Diffuse large B cell lymphoma; t(2; 17)

Indexed keywords

EID: 67650227517     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
2. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A, Nanba K, Takami T, Yamabe H, Takano Y, Izumo T, Nagatani T, Mohri N, Nasu K, Satoh H, Katano H, Yamamoto T and Mori S. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995;86:1954-1960.
3. Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C, Racaud-Sultan C, Gonzalez-Dunia D, Vigny M, Mehlen P, Delsol G and Allouche M. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 2006;26:6209-6222.
4. Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH and Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006;6: 448-461.
5. Souttou B, Carvalho NB, Raulais D and Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001; 276:9526-9531.
6. Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM and Hill DA. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001;25:1364-1371.
7. Tsuzuki T, Magi-Galluzzi C and Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2004;28:1609-1614.
8. Tan LH, Tan PH, Tan SY, Ventura R, Yip GW, Zhou YC, Do E, Koay ES, Kwan C, Poh BK and Peh S. Inflammatory myofibroblastic tumour of the bladder may express anaplastic lymphoma kinase by translocation-dependent and translocation-independent mechanisms: a report of two cases. Histopathology 2007;50: 278-282.
9. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T and Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999;59: 2776-2780.
10. Li XQ, Hisaoka M, Shi DR, Zhu XZ and Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum Pathol 2004;35:711-721.
11. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H. Identification of the transforming EML4-ALK fusion gene in non-small- cell lung cancer. Nature 2007;448:561-566.
12. George RE, Sanda T, Hanna M, Frohling S, Luther W, 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M and Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-978.
13. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M and Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935.
14. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G and Mariame B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-1721.
15. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J and Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-970.
16. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H and Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-974.
17. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW and Mason DY. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997;89:1483-1490.
18. Delsol G, Campo E and Gascoyne RD. ALK-positive large B-cell lymphoma. In: WHO Classification of Tumors of Haematopoietic and Lymphoid tissues (4th ed). Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stain H, Thiele J and Vardiman JW (Eds). IARC, Lyon, 2008. pp254-255
19. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink HK, Seymour JF, Campbell LJ, Horsman DE, Auvigne I, Espinos E, Siebert R and Delsol G. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003;102:2568-2573.
20. De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, De Wolf-Peeters C, Marynen P and Wlodarska I. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638-2641.
21. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H, Yamashita Y and Mori N. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol 2003;16:828-832.
22. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW, Kennedy W, Jones SC and Sandlund JT. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003;102:2642-2644.
23. Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C, Schmid M, Muller-Hermelink HK and Ott G. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 2003;27:1473-1476.
24. McManus DT, Catherwood MA, Carey PD, Cuthbert RJ and Alexander HD. ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum Pathol 2004;35:1285-1288.
25. Colomo L, Loong F, River S, Pittaluga S, Martinez A, Lopes-Guillermo A, Ojanguren J, Romagosa V, Jaffe ES and Campo E. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogenous group of disease entities. Am J Surg Pathol 2004;28: 736-747
26. Ishii K, Yamamoto Y and Nomura S. [CD30-negative diffuse large B-cell lymphoma expressing ALK]. Rinsho Ketsueki 2005;46: 501-506.
27. Rudzki Z, Rucinska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Pirog K, Utych G, Bodzioch P, Srebro-Stariczyk M, Wlodarska I and Stachura J. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol 2005; 56:37-45.
28. Gesk S, Gascoyne RD, Schnitzer B, Bakshi N, Janssen D, Klapper W, Martin-Subero JI, Parwaresch R and Siebert R. ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia 2005;19:1839-1840.
29. Isimbaldi G, Bandiera L, d'Amore ES, Conter V, Milani M, Mussolin L and Rosolen A. ALK-positive plasmablastic B-cell lymphoma with the clathrin-ALK gene rearrangement. Pediatr Blood Cancer 2006;46:390-391.
30. Bubala H, Maldyk J, Wlodarska I, Sonta-Jakimczyk D and Szczepanski T. ALK-positive diffuse large B-cell lymphoma. Pediatr Blood Cancer 2006;46:649-653.
31. Reichard KK, McKenna RW and Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 2007;20:310-319.
32. Stachurski D, Miron PM, Al-Homsi S, Hutchinson L, Harris NL, Woda B and Wang SA. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24. Hum Pathol 2007;38: 940-945.
33. Lee HW, Kim K, Kim W and Ko YH. ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol 2008;26:108-113.
34. Momose S, Tamaru J, Kishi H, Mikata I, Mori M, Toyozumi Y and Itoyama S. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol 2009;40:75-82.
35. Nasr MR, Laver JH, Chang M and Hutchison RE. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. Am J Clin Pathol 2007;127: 770-778.
36. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO and Weisenburger DD. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
37. Colomo L, Loong F, River S, Pittaluga S, Martinez A, Lopes-Guillermo A, Ojanguren J, Romagosa V, Jaffe ES and Campo E. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogenous group of disease entities. Am J Surg Pathol 2004;28: 736-747
38. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A and Marynen P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34:354-362.
39. Bellezza G, Cavaliere A, Del Sordo R and Sidoni A. Inflammatory myofibroblastic tumor of the larynx with anaplastic lymphoma kinase (ALK) protein overexpression. A case report. Tumori 2006;92:449-451.
40. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E and Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569-576.
41. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M and Morris SW. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-415.
42. Chiarle R, Voena C, Ambrogio C, Piva R and Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
43. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H and Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
44. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R and Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003;101:1919-1927.
45. Jager R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, Schorle H and Wellmann A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 2005;25:3191-3196.
46. Turner SD and Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005;19:1128-1134.
47. Turner SD, Merz H, Yeung D and Alexander DR. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 2006;26:3275-3279.
48. Turner SD, Tooze R, Maclennan K and Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003;22: 7750-7761.
49. Amin HM and Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110:2259-2267.
50. Wu F, Wang P, Young LC, Lai R and Li L. Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am J Pathol 2009; 174:361-370.
51. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and Wasik MA. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008;105:20852-20857.
52. Li R and Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008;28:372-412.
53. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B and Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6: 3314-3322.
54. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B and Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417.
55. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS and Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104: 270-275.